에 대한 최신 뉴스 Icon (NASDAQ:ICLR) 주식

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

News

Hedge Funds

Trading Ideas

BILL

CFLT

CRMD

ICLR

MSTR

NVDA

RING

WOLF

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 기술 노출을 재편했다. 미국 증권 거래 위원회에 제출된 새로운 13-F 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:

엘리엇 인베스트먼트가 울프스피드 주식을 매수하고 4분기에는 엔비디아 풋 옵션에 베팅

Equities

Large Cap

Short Sellers

Movers

BMRN

BNTX

FTAI

MRNA

NTRA

RGTI

RKLB

SNAP

1월 13일부터 17일까지 지난주에 가장 저조한 성과를 보인 대형주 11개 종목은 다음과 같다. FTAI 애비에이션 모더나 게임스탑 스냅 로켓랩 일라이 릴리 아이콘 바이오엔테크 노보 노디스크 바이오마린

모더나, 게임스탑, 스냅 등 지난주 급락한 대형주 (1월 13일~17일)

ETSY

MTCH

SDRL

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 여행 및 숙박에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.

엘리엇이 3분기에 웨스턴 디지털, 엣시는 추가; 씨드릴, 블랙라인, NRG 에너지는 축소

Icon PLC

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $275 to $240.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Icon, Lowers Price Target to $240

Editor's Note: This article has been updated to clarify that Elliott Investment Management purchased convertible senior notes of Wolfspeed and MicroStrategy.
Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm&#8217;s <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">technology exposure</a>.
According to a new&nbsp;<a href="https://www.sec.gov/Archives/edgar/data/1791786/000101359425000294/xslForm13F_X02/primary_doc.xml" target="_blank" rel="noreferrer noopener">13-F</a>&nbsp;filing with the U.S. Securities and Exchange Commission, Elliott added the following new positions in the fourth quarter:
<ul>
<li>Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) 0.25% and 1.875% convertible senior notes</li>
</ul>
<ul>
<li>NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) put options</li>
</ul>
<ul>
<li>SPDR Select Sector Fund Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) put options</li>
</ul>
<ul>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) put options</li>
</ul>
Here's a look at all of the positions Elliott added to during the fourth quarter:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) increased by 369%</li>
</ul>
<ul>
<li>MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) increased convertible senior notes by 200%</li>
</ul>
<ul>
<li>CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) increased by 85%</li>
</ul>
<ul>
<li>HDFC Bank Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) increased by 6%</li>
</ul>
Here&#8217;s a look at all of the positions Elliott closed during the fourth quarter:
<ul>
<li>Catalent Inc (CTLC) </li>
</ul>
<ul>
<li>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
</ul>
<ul>
<li>Unity Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>)</li>
</ul>
<ul>
<li>BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</li>
</ul>
Elliott closed out of calls in several names including Arm Holdings, American Airlines and Alaska Air Group. The firm also closed multiple put positions including Equinix, Hyatt Hotels and Host Hotels.
Here's a look at all of the positions Elliott trimmed during the fourth quarter:
<ul>
<li>ICON Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) decreased by 62%</li>
</ul>
<ul>
<li>RingCentral Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>) decreased by 55%</li>
</ul>
<ul>
<li>NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) decreased by 50%</li>
</ul>
<ul>
<li>Confluent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) decreased by 37%</li>
</ul>
<ul>
<li>Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) decreased by 2%</li>
</ul>
The above information does not include call or put options that were added to or trimmed&nbsp;during the quarter.
This information was gathered using comparison tools from&nbsp;<a href="https://13f.info/13f/000101359425000294/compare/000101359424000968" target="_blank" rel="noreferrer noopener">13f.info</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">5 Top Tech Stocks Hedge Funds Have Been Bullish On In Q4 (Hint: It&#8217;s Not Nvidia)</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Elliott Investment Management Bets Against Nvidia In Q4 (CORRECTED)

WIIM

Icon shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS estimate.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.43 per share which beat the analyst consensus estimate of $3.42 by 0.29 percent. This is a 0.87 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $2.04 billion which met the analyst consensus estimate. This is a 1.22 percent decrease over sales of $2.07 billion the same period last year.

Earnings

Earnings Beats

Icon Q4 2024 Adj EPS $3.43 Beats $3.42 Estimate, Sales $2.04B Inline

ACVA

AMPL

ANSS

APPN

BLCO

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $284 to $262.

Truist Securities Maintains Buy on Icon, Lowers Price Target to $262

JP Morgan analyst Casey Woodring maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $280 to $265.

JP Morgan Maintains Overweight on Icon, Lowers Price Target to $265

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

RBC Capital analyst Sean Dodge reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and maintains $263 price target.

Reiteration

RBC Capital Reiterates Outperform on Icon, Maintains $263 Price Target

ICON shares are trading lower after the company issued FY25 guidance with its midpoint below estimates.

Guidance

ICON Earlier Issued Guidance; Sees FY25 Revenue $8.05B-$8.65B vs $8.496B Est., Adj. EPS $13.00-$15.00 vs $14.83 Est.

Clinical research organization ICON plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) announced its financial guidance for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42971328/icon-issues-financial-guidance-for-full-year-2025" rel="noreferrer noopener">fiscal year 2025 on Tuesday</a>.
What Happened: The Dublin-based company forecasts revenues of $8.05 billion — $8.65 billion. This represents growth of about 1% at the midpoint compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.5 billion</a>.
The company expects adjusted earnings per share to be in the range of $13 to $15. That&#8217;s flat over the full-year 2024 adjusted earnings per share guidance midpoint compared to the consensus of $14.83.
See Also: <a href="https://www.benzinga.com/25/01/42980742/trump-off-hook-in-2020-election-case-special-counsel-smith-says-evidence-was-sufficient-to-obtain-and-sustain-a-conviction">Trump&#8217;s 2024 Election Win Spares Him From &#8216;Conviction&#8217; In Jan. 6 Case, Special Counsel Says</a>
ICON CEO Steve Cutler says trial activity has been &#8220;impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.&#8221; 
The company&#8217;s outlook for this year reflects an expected transition period, which includes a headwind from its top two customers on a combined basis, coupled with &#8220;an inconsistent recovery in biotech,&#8221; he added.
For fiscal year 2024, the company reaffirmed its current guidance of revenue of $8.26 billion — $8.3 billion and adjusted EPS of $13.90 &#8211; $14.10 versus consensus of $8.28 billion and $13.98, respectively.
Why It Matters: William Blair analysts are &#8220;surprised by the size of the topline cut relative to management&#8217;s initial thoughts last quarter (anticipated revenue growth in the low to mid-single digits for this year).&#8221;
Analyst Max Smock expects the company to face challenges in understanding &#8220;cautious spending patterns&#8221; from biopharma clients, including Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
There&#8217;s also uncertainty about when biotech demand will stabilize. Investors debate whether $14 or $15 per share was the right target for the quarter.
The initial guidance for next year will lean closer to $15, observers say. However, margins will face more pressure than expected.
Price Action: Icon stock is down 6.96% at $202.81 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Image: Shutterstock

Analyst Color

Health Care

General

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty

William Blair analyst Max Smock reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Outperform.

William Blair Reiterates Outperform on Iconto Outperform

ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders

Icon shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and announced a price target of $263.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Mike Lavery initiated coverage on The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with an Overweight rating and announced a price target of $74. Coca-Cola shares closed at $60.81 on Monday. <a href="https://www.benzinga.com/quote/KO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities analyst John McDonald initiated coverage on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold rating and announced a price target of $260. JPMorgan shares closed at $240.85 on Monday. <a href="https://www.benzinga.com/quote/JPM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Sean Dodge initiated coverage on ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with an Outperform rating and announced a price target of $263. Icon shares closed at $215.51 on Monday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Eliana Merle initiated coverage on Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy rating and announced a price target of $196. Ascendis Pharma shares closed at $140.28 on Monday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Ross Osborn initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with an Overweight rating and announced a price target of $9. Anteris Technologies shares closed at $5.61 on Monday. <a href="https://www.benzinga.com/quote/AVR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png" alt="" class="wp-image-721909" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-1024x486.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35-768x364.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07090849/image-35.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

ASND

This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

RBC Capital analyst Sean Dodge initiates coverage on Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform rating and announces Price Target of $263.

RBC Capital Initiates Coverage On Icon with Outperform Rating, Announces Price Target of $263

Citigroup analyst Patrick Donnelly maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $300 to $290.

Citigroup Maintains Buy on Icon, Lowers Price Target to $290

Truist Securities analyst Jailendra Singh reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $295 to $284.

Truist Securities Reiterates Buy on Icon, Lowers Price Target to $284

Barry will continue to report to ICON's Chief Executive Officer, Steve Cutler.

Management

ICON Appoints Barry Balfe As COO

Legal

Press Releases

DEADLINE ALERT for MPWR, GSK, and ICLR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Shareholders that lost money on ICON Public Limited Company (ICLR) should contact The Gross Law Firm about pending Class Action - ICLR

ICLR Investors are Suing ICON PLC; Contact Robbins LLP for More Information

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Public Limited Company Lawsuit - ICLR

ICLR Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds ICON Public Limited Company (ICLR) Investors that a Securities Fraud Class Action Lawsuit Has Been Filed

ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Shareholders of ICON Public Limited Company Should Contact Levi & Korsinsky Before April 11, 2025 to Discuss Your Rights – ICLR

INVESTOR ALERT: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ICLR

ICON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ICON plc - ICLR

ICLR CLASS ACTION DEADLINE: ICON plc Investors with Losses are Notified of Ongoing Lawsuit – Contact BFA Law by April 11 Deadline (NASDAQ:ICLR)

MPWR

Barclays

Truist Securities

JP Morgan

RBC Capital

Citigroup

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">기술 노출</a>을 재편했다.
미국 증권 거래 위원회에 제출된 새로운 <a href="https://www.sec.gov/Archives/edgar/data/1791786/000101359425000294/xslForm13F_X02/primary_doc.xml" target="_blank" rel="noreferrer noopener">13-F</a> 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:
<ul>
<li>울프스피드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>)</li>
</ul>
<ul>
<li>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 풋 옵션</li>
</ul>
<ul>
<li>SPDR Select Sector Fund Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) 풋 옵션</li>
</ul>
<ul>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) 풋 옵션</li>
</ul>
다음은 엘리엇이 4분기에 추가한 모든 포지션들이다:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 369% 증가</li>
</ul>
<ul>
<li>마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) 200% 증가</li>
</ul>
<ul>
<li>코메딕스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) 85% 증가</li>
</ul>
<ul>
<li>HDFC 은행 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) 6% 증가</li>
</ul>
다음은 엘리엇이 4분기에 청산한 모든 포지션들이다:
<ul>
<li>캐털렌트 (CTLC)</li>
</ul>
<ul>
<li>카디널 헬스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
</ul>
<ul>
<li>유니티 소프트웨어 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>)</li>
</ul>
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</li>
</ul>
엘리엇은 Arm 홀딩스, 아메리칸 항공 및 알래스카 에어 그룹 등의 여러 종목에서 콜 옵션을 청산했다. 또한 에퀴닉스, 하얏트 호텔 및 호스트 호텔 등의 여러 풋 포지션도 청산했다.
다음은 엘리엇이 4분기에 축소한 모든 포지션들이다:
<ul>
<li>아이콘 Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 62% 감소</li>
</ul>
<ul>
<li>링센트럴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>) 55% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 50% 감소</li>
</ul>
<ul>
<li>컨플루언트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) 37% 감소</li>
</ul>
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 2% 감소</li>
</ul>
위 정보에는 분기 동안 추가되거나 축소된 콜 또는 풋 옵션이 포함되어 있지 않다.
이 정보는 <a href="https://13f.info/13f/000101359425000294/compare/000101359424000968" target="_blank" rel="noreferrer noopener">13f.info</a> 의 비교 도구를 사용하여 수집되었습니다.
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/4%EB%B6%84%EA%B8%B0%EC%97%90-%ED%97%A4%EC%A7%80%ED%8E%80%EB%93%9C%EA%B0%80-%EA%B8%8D%EC%A0%95%EC%A0%81%EC%9C%BC%EB%A1%9C-%ED%8F%89%EA%B0%80%ED%95%9C-%EC%83%81%EC%9C%84-5%EA%B0%9C-%EA%B8%B0%EC%88%A0/" target="_blank" rel="noopener">4분기 헤지펀드가 긍정적으로 평가한 5대 기술주 (힌트: NVIDIA가 아닙니다)</a></li>
</ul>
이 그림은 Midjourney를 통해 인공지능으로 생성되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

1월 13일부터 17일까지 지난주에 가장 저조한 성과를 보인 대형주 11개 종목은 다음과 같다.
<ol>
<li>FTAI 애비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>): 지난주 35.42% 급락했다. 이는 공매도 전문 회사인 머디 워터스 리서치(Muddy Waters Research)가 회사에 <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">공매도 포지션을 시작했다고 발표</a>한 후 발생했다.</li>
<li>모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): 지난주 19.38% 급락했다. 회사가 2025년 예상 매출 범위를 15억 달러에서 25억 달러로 업데이트한 것이 <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">애널리스트 추정치 29억 5천만 달러</a>보다 낮았기 때문이다. 모건스탠리는 중립 의견을 유지하고 <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 70달러에서 38달러로 하향 조정</a>했다.</li>
<li>게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>): 지난주 14.86% 하락했다. 최근 CNBC의 짐 크레이머가 소셜미디어 엑스(X)에 게시한 글에서 투자자들에게 <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">양자 주식으로 재투자할 것을 권유</a>하며 게임스탑에서 얻은 수익을 리제티 컴퓨팅(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)에 재투자하라고 제안했다.</li>
<li>스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>): 지난주 12.91% 하락했다. 이는 트럼프가 틱톡을 미국 금지에서 구하기 위한 행정명령을 고려하고 있다는 보도가 나온 후 발생한 일이다.</li>
<li>로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>): 지난주 10.81% 하락했다. 로켓랩은 발다 스페이스 인더스트리(Varda Space Industries)를 위한 두 번째 파이오니어(Pioneer) 우주선이 <a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener">궤도에서 성공적으로 작동 중이다</a>고 발표했다.</li>
<li>나테라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 구겐하임이 <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 170달러에서 200달러로 상향 조정</a>한 것에도 불구하고 지난주 9.51% 하락했다. 회사는 J.P. 모건 헬스케어 컨퍼런스에서 로드맵과 전망을 제공할 예정이다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): 지난주 9.27% 하락했다. 회사가 2024년 매출 전망을 <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">이전 예상보다 낮게 발표</a>한 후 발생했다.</li>
<li>아이콘(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>): 지난주 9.22% 하락했다. 회사가 2025년 가이던스를 발표했을 때 <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">중간값이 예상치보다 낮았기 때문이다.</a></li>
<li>바이오엔테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>): 지난주 8.89% 하락했다. 이는 모더나가 2025년 매출 전망을 <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">애널리스트 예상보다 낮게 발표</a>한 후 발생한 일이다.</li>
<li>노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>): 지난주 8.89% 하락했다. 이번 하락은 오젬픽(Ozempic)과 위고비(Wegovy)가 <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">메디케어 약가 협상 목록</a>에 포함되었다는 발표 후 나타났다.</li>
<li>바이오마린 파마슈티컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>): 지난주 8.68% 급락했다. 회사는 어센디스 파마(Ascendis Pharma A/S)에 대해 유럽 특허 EP 3 175 863 B1 침해로 <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">독일 뮌헨 통합 특허 법원에서 법적 조치를 취했다</a>고 발표했다.</li>
</ol>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

엘리엇 인베스트먼트 매니지먼트(Elliott Investment Management)는 3분기에 분주했다. 미 증권거래위원회(SEC)에 새로 제출한 13-F에 따르면 이 행동주의 투자자는 <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">여행 및 숙박</a>에 초점을 맞춘 여러 가지 새로운 포지션을 포함하여 여러 가지 포트폴리오 전환을 수행했다.
여기 3분기에 엘리엇이 새로 취득한 모든 포지션이 있다:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) 콜 옵션</li>
</ul>
<ul>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) 콜 옵션</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) 콜 옵션</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) 콜 옵션</li>
</ul>
<ul>
<li>알래스카 에어 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) 콜 옵션</li>
</ul>
<ul>
<li>아메리칸 항공 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이콘 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) 콜 옵션</li>
</ul>
<ul>
<li>아이큐비아 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) 콜 옵션</li>
</ul>
<ul>
<li>메리어트 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) 풋 옵션</li>
</ul>
<ul>
<li>힐튼 월드와이드 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) 풋 옵션</li>
</ul>
<ul>
<li>에퀴닉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) 풋 옵션</li>
</ul>
<ul>
<li>하얏트 호텔 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) 풋 옵션</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) 풋 옵션</li>
</ul>
3분기 동안 엘리엇이 늘린 모든 포지션을 살펴보겠다:
<ul>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) 919% 증가</li>
</ul>
<ul>
<li>웨스턴 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) 90% 증가</li>
</ul>
<ul>
<li>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) 11% 증가</li>
</ul>
<ul>
<li>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) 3% 증가</li>
</ul>
이번 분기에 엘리엇이 줄인 모든 포지션은 다음과 같다:
<ul>
<li>빌 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) 24% 감소</li>
</ul>
<ul>
<li>블랙라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) 20% 감소</li>
</ul>
<ul>
<li>씨드릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) 9% 감소</li>
</ul>
<ul>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 7% 감소</li>
</ul>
위의 정보는 분기 동안 증가하거나 줄어들거나 완전히 매도된 콜 또는 풋 옵션을 포함하지 않았다.
이 정보는 <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>의 비교 도구를 사용하여 수집되었습니다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">넬슨 펠츠의 트라이언 펀드 매니지먼트가 대선 전 포트폴리오를 재편성</a></li>
</ul>
사진: Pixabay.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아이콘(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>)의 주식은 <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 실적</a>을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
2. 제뉴인 파츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>)의 주식은 엇갈린 3분기 실적과 <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 낮은 2024년 EPS</a>를 발표한 후 20.21% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
3. 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)의 주식은 <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 15.97% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 지난주 14.71% 하락했다. 몇몇 헬스케어 주식과 병원 운영자들은 3분기 실적이 감소한 HCA 헬스케어에 동조세 가능성이 있었다.
5. 유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)의 주식은 <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 지난주 14.33% 하락했다.
6. HCA 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>)의 주식은 <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 재무 실적</a>을 발표한 후 12.51% 하락했다. 이 회사는 허리케인 헬렌의 영향이 2025년까지 지속될 것으로 예상하고 있다.
7. 탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주식은 허리케인 밀턴의 영향으로 주택 건설 주식이 <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">타격을 받은 후</a> 11.48% 하락했다.
8. 칼라일 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>)의 주식은 <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 실적</a> 발표 후 11.45% 하락했다.
9. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주식은 <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 11.34% 하락했다. 일부 애널리스트들은 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
10. 컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주식은 <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 매출 실적</a>을 발표한 후 11.27% 하락했다.
추가로 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)

Comments

Icon

뉴스

에 대한 최신 뉴스 Icon (NASDAQ:ICLR) 주식

목요일, 2월 20, 2025

월요일, 1월 20, 2025

금요일, 11월 15, 2024

토요일, 10월 26, 2024

뉴스

파트너 / 기고자

벤징가 글로벌